Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Achieving Innovation in CLL Care Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

Recorded on Friday, December 10, 2021

Join CLL Society and PeerView Institute to watch the ASH 2021 Symposium about the newest data on BTK inhibitors and CAR-T cell constructs in CLL Treatment.

Continuous or fixed duration therapy with targeted agents (including BTK, PI3K, and BCL-2 inhibitors) in chronic lymphocytic leukemia (CLL) has overturned the decades-long consensus centered on chemoimmunotherapy and decisively become the new standard of care. This CME-certified live Seminars and Tumor Board event features a panel of leading CLL experts who, mimicking the collaborative nature of real-world tumor boards, will blend serial, case-based discussion with mini seminars designed to illustrate how fully integrating targeted therapeutics—including BTK, PI3K, and BCL-2 inhibitors, as well as novel antibodies—can improve care across the clinical spectrum of CLL. Panelists cover important clinical topics such as the personalized, evidence-based selection of upfront treatment strategies, therapeutic sequencing in progressive disease settings, safety management and distinctions among agent classes, the use of MRD assessment as a treatment tool, and next-generation and novel combination strategies.

Register to watch the webcast below!